Internal Medicine, Infectious Disease · Chicago, IL
NPI
1346236379
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2900 N Lake Shore Dr, Suite 1231
Chicago, IL, 60657
Phone (773) 665-3261
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
2,363 services
Medicare patients, 2024
135
Average age 72
Drug cost, 2024
$4.7M
2,864 prescriptions
Company payments, 2025
$15K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James F Sullivan was code G0316 (prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th), 787 times for 67 patients. In total James F Sullivan billed 2,363 services in 24 codes, and Medicare paid $133K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G0316 Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 787 | 67 | $24.72 | $19K |
| 99233 Hospital E&M - Subsequent | Facility | 572 | 79 | $97.26 | $56K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 487 | 68 | $25.50 | $12K |
| 99215 Office E&M - Established | Office | 204 | 71 | $129.74 | $26K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 136 | 58 | $12.99 | $1,766 |
| 99223 Hospital E&M - Initial | Facility | 78 | 73 | $141.94 | $11K |
| 99232 Hospital E&M - Subsequent | Facility | 44 | 12 | $64.82 | $2,852 |
| 99214 Office E&M - Established | Office | 12 | 11 | $77.77 | $933 |
By year: 2022 $144K for 1,738 services; 2023 $109K for 1,738 services; 2024 $133K for 2,363 services.
Medicare prescription drug claims, 2024
In 2024, the drug James F Sullivan prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 313 prescriptions and refills. In total James F Sullivan wrote 2,864 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 313 | 339 | 33 | $1.4M |
| Descovy Emtricitabine/Tenofov Alafenam | 220 | 230 | 22 | $534K |
| Tivicay Dolutegravir Sodium | 212 | 220 | 21 | $556K |
| Prezcobix Darunavir/Cobicistat | 164 | 164 | 17 | $431K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 96 | 116 | 11 | $556K |
| Maraviroc Generic | 84 | 94 | Under 11 | $112K |
| Rosuvastatin Calcium Generic | 83 | 207 | 20 | $1,471 |
| Pifeltro Doravirine | 81 | 81 | Under 11 | $146K |
| Darunavir Generic | 80 | 80 | Under 11 | $68K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 75 | 75 | 11 | $3,350 |
| Ritonavir Generic | 55 | 59 | Under 11 | $4,477 |
| Ertapenem Ertapenem Sodium | 49 | 49 | Under 11 | $41K |
| Atorvastatin Calcium Generic | 46 | 108 | 13 | $444 |
| Acyclovir Generic | 46 | 77 | Under 11 | $417 |
| Valacyclovir Valacyclovir Hcl | 44 | 66 | Under 11 | $2,766 |
Brand drugs: 1,469 claims; generic drugs: - claims; opioid claims: 75.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James F Sullivan $15K ($15K in general payments such as food, travel and fees) from 11 companies. The largest payer was Gilead Sciences, Inc. with $13K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 35 | $13K |
| ViiV Healthcare Company GSK | 19 | $370 |
| Merck Sharp & Dohme LLC MRK | 8 | $213 |
| Abbvie Inc. ABBV | 5 | $146 |
| Theratechnologies Inc. THTX | 4 | $107 |
| Napo Pharmaceuticals Inc | 4 | $99.56 |
| Melinta Therapeutics, LLC | 3 | $86.35 |
| Shionogi Inc 4507.T | 2 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $42.05 |
| Boston Scientific Corporation BSX | 1 | $34.11 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.